Assertio Holdings, Inc., based in the United States, is a high-risk pharmaceutical company with an ESG score of 34.1. Specializing in neurology, orphan, and specialty medicines, it offers FDA-approved products like Gralise, CAMBIA, and Zipsor for various neurological conditions. Advance patient care with Assertio Holdings, Inc.